Meeting
2018 ASCO Annual Meeting
Phase I study of procaspase activating compound-1 (PAC-1) for treatment of advanced malignancies.
Authors
Oana C. Danciu
University of Illinois at Chicago, Chicago, IL
Oana C. Danciu , Martin Kelly Nicholas , Matthias Holdhoff , Richard A. Peterson , Theodore M Tarasow , Paul J. Hergenrother , Arkadiusz Z. Dudek
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT02355535
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS2621)
DOI
10.1200/JCO.2018.36.15_suppl.TPS2621
Abstract #
TPS2621
Poster Bd #
434b
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Phase I study of procaspase activating compound -1 (PAC-1) in combination with temozolomide (TMZ) for the treatment of recurrent malignant glioma.
First Author: Martin Kelly Nicholas
Poster
2015 ASCO Annual Meeting
Phase I study of procaspase activating compound-1 (PAC-1) in the treatment of advanced malignancies.
First Author: Oana C. Danciu
Poster
2016 ASCO Annual Meeting
Phase I study of procaspase activating compound -1 (PAC-1) in the treatment of advanced malignancies.
First Author: Oana Cristina Danciu
Poster
2022 ASCO Annual Meeting
Phase I study of drug-resistant immunotherapy (DRI) with gene-modified autologous γδ T cells in patients with newly diagnosed glioblastoma multiforme (GBM) receiving maintenance temozolomide (TMZ).
First Author: Louis B. Nabors